| Literature DB >> 35684037 |
Meijuan Lan1,2, Lin Li2,3, Shengkai Luo2, Juncheng Chen2, Xiaofeng Yi4, Xia Zhang2, Bing Li2, Zhiyi Chen1.
Abstract
In this study, the physicochemical properties, fatty acid composition, antioxidant activities, and in vitro as well as in vivo toxicological safety of emu oil were investigated. Emu oil was shown to have a low acid and peroxide value, low amounts of carotenoid and phenolic compounds, and high doses of oleic acid and linoleic acid. Furthermore, in a bacterial reverse mutation assay, emu oil demonstrated no change in the amount of revertant colonies for all strains. In a chromosomal assay, no aberrations occurred in any of the emu oil treatment groups (1.25, 2.5, and 5 μg/mL). In the bone marrow micronucleus test, emu oil up to 20 mL/kg showed no significant increase in the incidence of micronucleated polychromatic erythrocytes. Moreover, emu oil up to 19.3 mg/kg body weight did not affect body weight in an acute oral toxicity study. These results are crucial for the adoption of emu oil as an alternative source of edible oil.Entities:
Keywords: antioxidant activities; emu oil; fatty acid; toxicological safety
Mesh:
Substances:
Year: 2022 PMID: 35684037 PMCID: PMC9182831 DOI: 10.3390/nu14112238
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 6.706
Physicochemical properties of emu oil.
| Emu Oil | Lard | Tallow | |
|---|---|---|---|
| Item | Concentration | ||
| Acid value | 1.24 ± 0.49 | 0.63 a | 1.07 a |
| Free fatty acid content (%) | 0.80 ± 0.07 | 10.03 b | 3.19 b |
| MDA | 0.02 ± 0.01 | 0.05 c | N/A |
| Peroxide value | 1.50 ± 1.46 | 3.67 d | 0.65 d |
| Iodine value | 72.67 ± 2.08 | 77.90 a | 45.30 a |
| Unsaponified matter (%) | 0.54 ± 0.13 | 12 e | 0–0.5 e |
| Refractive index (40 °C) | 1.46 ± 0.01 | 1.45–1.46 e | 1.45–1.46 e |
| Carotenoid content (mg/kg oil) | 5.92 ± 0.62 | N/A | N/A |
| Total phenolic content | 6.64 ± 0.37 | N/A | N/A |
a–e: data source; a [25]; b [26]; c [24]; d [27]; e [28]. N/A: data not available.
Fatty acid composition of emu oil.
| Emu Oil | Lard a | Tallow b | |
|---|---|---|---|
| Fatty Acid | % Total Fatty Acids | ||
| Saturated fatty acid | 34.78 ± 1.04 | 52.10 | 48.00 |
| Palmitic acid (C16:0) | 25.67 ± 1.11 | 26.86 | 28.40 |
| Heptadecanoic acid (C18:0) | 9.06 ± 0.04 | N/A | 14.80 |
| Docosanoic acid (C22:0) | 0.05 ± 0.03 | 0.27 | 14.8 |
| Unsaturated fatty acid | 64.28 ± 1.04 | 47.41 | 52.00 |
| Palmitoleic acid (C16:1 cis) | 4.08 ± 1.11 | 1.52 | 4.7 |
| Heptadecenoic acid (C17:1) | 0.06 ± 0.03 | N/A | N/A |
| Oleic acid | 45.76 ± 0.53 | 33.71 | 44.6 |
| Linoleic acid | 14.00 ± 0.21 | 10.90 | 2.7 |
| Linolenic acid (C18:3 cis) | 0.37 ± 0.28 | 0.49 | N/A |
a and b: data source; a [29]; b [30]. N/A: data not available.
Figure 1Radical scavenging activities of emu oil. (a) DPPH free radical scavenging activity assay, and (b) ABTS radical scavenging activity assay.
Bacterial reverse mutation assay of emu oil.
| Treatment (μg/Plate) | TA97a | TA98 | TA100 | TA102 | TA1535 | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| −S9 | +S9 | −S9 | +S9 | −S9 | +S9 | −S9 | +S9 | −S9 | +S9 | |
| Revertants per plate a | ||||||||||
| Main test | ||||||||||
| Vehicle control b | 183 ± 3 | 183 ± 9 | 17 ± 1 | 19 ± 7 | 167 ± 10 | 190 ± 20 | 358 ± 14 | 268 ± 44 | 17 ± 4 | 21 ± 7 |
| 5000 | 196 ± 13 | 184 ± 18 | 20 ± 13 | 18 ± 2 | 161 ± 22 | 185 ± 46 | 289 ± 18 | 243 ± 27 | 19 ± 3 | 16 ± 3 |
| 1581 | 186 ± 17 | 191 ± 20 | 20 ± 5 | 16 ± 5 | 175 ± 15 | 160 ± 13 | 296 ± 63 | 246 ± 14 | 16 ± 3 | 12 ± 3 |
| 500 | 177 ± 12 | 165 ± 14 | 17 ± 2 | 30 ± 18 | 167 ± 17 | 162 ± 13 | 317 ± 31 | 197 ± 10 | 19 ± 1 | 14 ± 1 |
| 158.1 | 183 ± 6 | 163 ± 16 | 23 ± 4 | 21 ± 7 | 155 ± 28 | 174 ± 19 | 278 ± 76 | 208 ± 20 | 17 ± 6 | 16 ± 3 |
| 50 | 159 ± 28 | 162 ± 26 | 15 ± 4 | 23 ± 5 | 161 ± 19 | 166 ± 27 | 276 ± 39 | 243 ± 22 | 17 ± 2 | 13 ± 2 |
| Positive control c | 1556 ± 156 * | 715 ± 211 * | 947 ± 249 * | 1365 ± 171 * | 1145 ± 123 * | 876 ± 27 * | 3501 ± 649 * | 1318 + 72 * | 75 ± 12 * | 258 ± 39 * |
| Confirmatory test | ||||||||||
| Vehicle control b | 181 ± 10 | 163 ± 18 | 17 ± 3 | 15 ± 4 | 171 ± 29 | 149 ± 44 | 389 ± 51 | 359 ± 26 | 21 ± 6 | 14 ± 4 |
| 5000 | 176 ± 7 | 199 ± 4 | 13 ± 3 | 19 ± 4 | 171 ± 26 | 158 ± 29 | 413 ± 19 | 415 ± 32 | 13 ± 2 | 14 ± 2 |
| 1000 | 153 ± 5 | 173 ± 23 | 20 ± 5 | 12 ± 2 | 178 ± 17 | 151 ± 30 | 383 ± 22 | 375 ± 24 | 14 ± 4 | 16 ± 6 |
| 200 | 166 ± 17 | 173 ± 5 | 19 ± 3 | 16 ± 1 | 145 ± 24 | 175 ± 17 | 389 ± 32 | 302 ± 67 | 10 ± 6 | 14 ± 4 |
| 40 | 158 ± 9 | 176 ± 4 | 18 ± 5 | 15 ± 4 | 177 ± 12 | 157 ± 9 | 377 ± 44 | 282 ± 52 | 13 ± 5 | 16 ± 2 |
| 8 | 154 ± 14 | 170 ± 9 | 17 ± 4 | 18 ± 4 | 199 ± 21 | 142 ± 36 | 395 ± 17 | 317 ± 9 | 8 ± 3 | 14 ± 3 |
| Positive control c | 1237 ± 223 * | 565 ± 53 * | 739 ± 119 * | 1000 ± 66 * | 796 ± 243 * | 947 ± 104 * | 1936 ± 354 * | 1076 ± 76 * | 91 ± 11 * | 104 ± 14 * |
a All numbers represent means ± standard deviation (n = 3). b The vehicle control was 100 uL DMSO. c Positive controls for each strain were: for strains TA97a and TA100/−S9, 4-nitro-1,2-phenylenediamine monohydrochloride (40 μg/plate); TA98/−S9, 2-aminofluorene (5 μg/plate); for TA102/−S9, mitomycin C (1 μg/plate); for TA1535/−S9, 4-nitroquinoline-N-oxide (1 μg/plate); for strains TA97a, TA98, TA100 and TA1535/+S9, 2-aminofluorene (5 μg/plate); for TA102/+S9, 1,8-dihydroxyanthraquinone (50 μg/plate). * Significantly different from the vehicle control at p < 0.05.
Figure 2Types of chromosomal aberration for cell under microscope. (a). chromatid exchange (CTE) and ring (R); (b). chromatid exchange (CTE) and translocation (T); (c). chromatid break (CTB) and translocation (T).
Summary results of chromosome aberration assay in Chinese hamster lung (CHL) cells treated with emu oil.
| Exposure | Treatment | No. of Metaphases Scored | No. of Metaphases with Different Aberration Types | ||||
|---|---|---|---|---|---|---|---|
| No. of Metaphases with Aberrations | Breaks | Exchanges | Gaps | ||||
| Ring Chromosome | Chromatid Exchanges | ||||||
| 2 (Without S9 mix) | MEM (200 μL) | 100 | 0 | 0 | 0 | 0 | 0 |
| Emu oil (1.25 μL/mL) | 100 | 0 | 0 | 0 | 0 | 0 | |
| Emu oil (2.50 μL/mL) | 100 | 0 | 0 | 0 | 0 | 0 | |
| Emu oil (5.00 μL/mL) | 100 | 0 | 0 | 0 | 0 | 0 | |
| Mitomycin C | 100 | 10 ** | 1 ** | 3 ** | 25 ** | 0 | |
| 2 (With S9 mix) | MEM (200 μL) | 100 | 0 | 0 | 0 | 0 | 0 |
| Emu oil (1.25 μL/mL) | 100 | 0 | 0 | 0 | 0 | 0 | |
| Emu oil (2.50 μL/mL) | 100 | 0 | 0 | 0 | 0 | 0 | |
| Emu oil (5.00 μL/mL) | 100 | 0 | 0 | 0 | 0 | 0 | |
| Cyclophosphamide | 100 | 10 ** | 0 | 1 ** | 12 ** | 0 | |
Abbreviations: MEM, Minimum Essential Media. ** Significant difference from the MEM at p < 0.01.
Summary results of micronucleus test conducted on emu oil.
| Treatment | Dose | No. of | Rate of PCE a
| Rate of MPCE b
|
|---|---|---|---|---|
| Male | ||||
| Vehicle control (corn oil) | 0 | 5 | 58.2 ± 5.3 | 0.6 ± 0.2 |
| Emu oil | 5 mL/kg | 5 | 51.6 ± 5.7 | 0.8 ± 0.4 |
| Emu oil | 10 mL/kg | 5 | 58.7 ± 11.9 | 0.9 ± 0.7 |
| Emu oil | 20 mL/kg | 5 | 54.7 ± 7.3 | 1.3 ± 0.8 |
| Positive control (cyclophosphamide) | 40 mg/kg | 5 | 56.7 ± 6.2 | 22.5 ± 11.9 ** |
| Female | ||||
| Vehicle control (corn oil) | 0 | 5 | 49.5 ± 5.1 | 0.5 ± 0.4 |
| Emu oil | 5 mL/kg | 5 | 56.0 ± 3.3 | 0.9 ± 0.7 |
| Emu oil | 10 mL/kg | 5 | 56.9 ± 8.4 | 0.7 ± 0.4 |
| Emu oil | 20 mL/kg | 5 | 53.1 ± 5.3 | 1.6 ± 1.2 |
| Positive control (cyclophosphamide) | 40 mg/kg | 5 | 55.6 ± 4.9 | 21.0 ± 5.5 ** |
a PCE = polychromatic erythrocytes. b MPCE = number of micronucleated polychromatic erythrocytes observed per 2000 polychromatic erythrocytes examined. ** Significant difference from the cyclophosphamide at p < 0.01.
Figure 3Body weight of mice supplemented with emu oil in the acute toxicity test. Letters on the bar within the same form of emu oil indicate significant differences (p < 0.05).
General appearance and behavioral observations of the animal treated orally with emu oil in the acute test.
| Observation | Male | Female |
|---|---|---|
| Eye color | No effect | No effect |
| Urination | Normal | Normal |
| Rate of respiration | Normal | Normal |
| Change in skin | No effect | No effect |
| Diarrhea | Not present | Not present |
| General physique | Normal | Normal |
| Death | Alive | Alive |